R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with
thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma
PURPOSE: This phase II trial is studying how well giving rituximab together with combination
chemotherapy followed by thalidomide works in treating patients with previously untreated
mantle cell lymphoma.